Cleaves the membrane-bound precursor of TNF-alpha to its mature soluble form. Responsible for the proteolytical release of soluble JAM3 from endothelial cells surface. Responsible for the proteolytic release of several other cell-surface proteins, including p75 TNF-receptor, interleukin 1 receptor type II, p55 TNF-receptor, transforming growth factor-alpha, L-selectin, growth hormone receptor, MUC1 and the amyloid precursor protein. Acts as an activator of Notch pathway by mediating cleavage of Notch, generating the membrane-associated intermediate fragment called Notch extracellular truncation (NEXT). Plays a role in the proteolytic processing of ACE2. Plays a role in hemostasis through shedding of GP1BA, the platelet glycoprotein Ib alpha chain. Mediates the proteolytic cleavage of LAG3, leading to release the secreted form of LAG3. Ubiquitously expressed. Expressed at highest levels in adult heart, placenta, skeletal muscle, pancreas, spleen, thymus, prostate, testes, ovary and small intestine, and in fetal brain, lung, liver and kidney. 2 alternatively spliced human isoforms have been reported. Note: This description may include information from UniProtKB.
Protein type: EC 184.108.40.206; Membrane protein, integral; Motility/polarity/chemotaxis; Protease
Alt. Names/Synonyms: a disintegrin and metallopeptidase domain 17; a disintegrin and metalloprotease domain 17; a disintegrin and metalloproteinase domain 17 (tumor necrosis factor, alpha, converting enzyme); ADA17; ADAM 17; ADAM metallopeptidase domain 17; Adam17; Disintegrin and metalloproteinase domain-containing protein 17; Tace; TNF-alpha convertase; TNF-alpha converting enzyme; TNF-alpha-converting enzyme